Company profile: Circulomics
1.1 - Company Overview
Company description
- Provider of micro- and nanotechnology-driven solutions for nucleic acid sample preparation and long-read sequencing, offering Nanobind high molecular weight DNA extraction from plant, animal, and microbial samples, library preparation protocols, services for single chromosomal genome assemblies, and applications leveraging optical mapping for genome structure analysis.
Products and services
- High Molecular Weight DNA Extraction: Circulomics produces micro- and nanotechnology-enabled methods and kits to isolate high molecular weight DNA compatible with long-read sequencing platforms and optical mapping workflows
- Single Chromosomal Genome Assemblies: Circulomics delivers long-read-compatible services and technologies that achieve single chromosomal genome assemblies using extracted high molecular weight DNA
- Nanobind: Circulomics architects a nanotechnology-based platform that extracts high molecular weight DNA from plant, animal, and microbial specimens for long-read sequencing and optical mapping applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Circulomics
Mitotyping Technologies
HQ: United States
Website
- Description: Provider of forensic DNA analysis services for the criminal justice system, forensic laboratories, and anthropological applications, including mitochondrial DNA testing from small samples such as 2mm hair fragments or single teeth.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mitotyping Technologies company profile →
NeoPhore
HQ: United Kingdom
Website
- Description: Provider of novel small molecule cancer therapies that stimulate the immune system by targeting DNA mismatch repair to induce neoantigen expression and increase immunogenicity in solid tumors, including PMS2 and MLH1 modulators that convert immune-cold tumors to hot and enhance sensitivity to immune checkpoint inhibitors, plus continuous neoantigen creation and research and development on next-generation targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoPhore company profile →
Chroma Medicine
HQ: United States
Website
- Description: Provider of genetic medicines built on an epigenetic editing platform that uses programmable editors to silence, activate, or regulate multiple genes by controlling chromatin conformation; single-dose genomic medicines for precise, predictable, durable treatment; multiplex epigenetic editing to enhance allogeneic CAR T cells; and a PCSK9-targeted editor to lower cholesterol and LDL-C.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chroma Medicine company profile →
WellGen
HQ: United States
Website
- Description: Provider of plant-based wellness products discovered and developed using nutrigenomics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WellGen company profile →
Renova Therapeutics
HQ: United States
Website
- Description: Provider of gene therapies for chronic diseases, focusing on cardiovascular and metabolic indications. Offerings include RT-100, a single-dose therapy to improve heart function in congestive heart failure; RT-200, a single intravenous therapy to normalize blood glucose in Type 2 Diabetes Mellitus; and paracrine gene therapy enabling systemic delivery of therapeutic genes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Renova Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Circulomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Circulomics
2.2 - Growth funds investing in similar companies to Circulomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Circulomics
4.2 - Public trading comparable groups for Circulomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →